Sky Medipharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 29.10%
- Profit Growth 369.85%
- Ebitda 105.59%
- Net Worth 21.97%
- Total Assets 20.46%
About Sky Medipharma
Sky Medipharma Private Limited (SMPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 April 2011 and has a history of 13 years and ten months. Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Amit Narain and Sumit Narain serve as directors at the Company.
Company Details
-
Location
Kanpur Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74120UP2011PTC044320
-
Company No.
044320
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Apr 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Sky Medipharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Narain
|
Director | 12-Aug-2013 | Current |
|
Sumit Narain
|
Whole-Time Director | 11-Apr-2011 | Current |
Financial Performance of Sky Medipharma.
Sky Medipharma Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 29.1% increase. The company also saw a substantial improvement in profitability, with a 369.85% increase in profit. The company's net worth Soared by an impressive increase of 21.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sky Medipharma?
In 2016, Sky Medipharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Model Medical Diagnostics Private Limited (Opc)Amit Narain is a mutual person
-
Dr. Dwivedi Clinic Private Limited
Amit Narain is a mutual person
-
Model Medical Services Private Limited
Amit Narain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sky Medipharma?
Unlock and access historical data on people associated with Sky Medipharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sky Medipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sky Medipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
